Xhance (Fluticasone Propionate) Patent Expiration, LOE Window & CMS Spending

Xhance (Fluticasone Propionate) by Paratek: FDA Orange Book LOE 2036-02-23, 5 AB generics, $30.6M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorParatek
FDA Application & PathwayN209022 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-02-23
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$30.6M
2024 Medicare Part D Spend$19.9M
2024 Medicaid Spend$10.7M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 16.0% 2-yr change)